Comparison of Survival Outcomes of Early‐Stage Non‐Small‐Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection
World Journal of Surgery · 2025
DOI: 10.1002/wjs.12584 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift World Journal of Surgery, 2025. Verfasst von Guo-Jun Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, Nanchong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonectomy, Radiosurgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Shenzhen Medical Research Special Funds, The National Natural Science Foundation of China Young Scientist Grant, Nanchong Science and Technology Bureau Municipal School Cooperation Program.
Abstract (Originalsprache)
Objective
To evaluate the survival outcomes of stereotactic body radiotherapy (SBRT) versus surgical resection in elderly patients (≥ 70 years old) with early‐stage non‐small‐cell lung cancer (NSCLC).
Methods
A systematic search was conducted across databases such as PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, VIP, and Wanfang to collect comparative studies on the survival outcomes of SBRT versus surgery for early‐stage NSCLC in elderly patients, with searches up to December 2023 and statistical analysis performed using Stata software. This meta‐analysis included 10 comparative studies, encompassing 9410 elderly patients with early‐stage NSCLC.
Results
The results indicated that the SBRT group had worse outcomes compared to the surgery group in terms of 3‐year overall survival (OS) [HR = 1.31, 95% CI (1.02–1.70), p < 0.05], 5‐year OS [HR = 1.37, 95% CI (1.06–1.77), p < 0.05], 1‐year cancer‐specific survival (CSS) [HR = 1.32, 95% CI (1.03–1.68), p < 0.05], 3‐year CSS [HR = 1.89, 95% CI (1.70–2.11), p < 0.01], and 5‐year CSS [HR = 1.92, 95% CI (1.75–2.10), p < 0.01]. There were no statistically significant differences between the two groups in terms of 1‐year OS, 1‐year, 3‐year, and 5‐year progression‐free survival (PFS), and locoregional control (LC) rates ( p > 0.05).
Conclusion
For elderly early‐stage NSCLC patients with acceptable risk, surgery remains the more appropriate treatment method. For patients unable to undergo surgery or who refuse it, SBRT serves as a viable alternative treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, Nanchong, China.
- Motor Robotics Institute (MRI), South China Hospital, Shenzhen University, Shenzhen, China.
- Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, China.
ORCID-Profile: Guo-Jun Wu
Förderung
- Shenzhen Medical Research Special Funds
- The National Natural Science Foundation of China Young Scientist Grant
- Nanchong Science and Technology Bureau Municipal School Cooperation Program
Zitieren
APA
Wu, G. J., Zhang, Y., Liang, R., Peng, L., & Zhang, S. H. (2025). Comparison of Survival Outcomes of Early‐Stage Non‐Small‐Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection. World Journal of Surgery. https://doi.org/10.1002/wjs.12584
Vancouver
Wu GJ, Zhang Y, Liang R, Peng L, Zhang SH. Comparison of Survival Outcomes of Early‐Stage Non‐Small‐Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection. World Journal of Surgery. 2025. doi:10.1002/wjs.12584
BibTeX
@article{Wu2025,
author = {Wu, Guo-Jun and Zhang, Yi and Liang, Rui and Peng, Lei and Zhang, Shao-Hua},
title = {Comparison of Survival Outcomes of Early‐Stage Non‐Small‐Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection},
journal = {World Journal of Surgery},
year = {2025},
doi = {10.1002/wjs.12584}
}
EUVIMED